• 제목/요약/키워드: Internal Dose

검색결과 1,337건 처리시간 0.033초

시험관내 폐암(肺癌), 위암(胃癌) 및 신경교종(神經膠腫) 세포(細胞)에 대한 석웅황(石雄黃)의 항암효과(抗癌效果) (Induction of Apoptosis by Realgar on Lung Cancer Cells(A549), Stomach Center Cells(KATO) and Neuroglioma Cells(SNU-1118, U-87MG, U-373MG))

  • 방대건;김진성;류봉하
    • 대한한방내과학회지
    • /
    • 제28권2호
    • /
    • pp.294-303
    • /
    • 2007
  • Objectives : We are aimed to identify anti-tumor effects of realgar on some kinds of cancer cells through molecular biologic methods. Materials & Methods : We used 5 kinds of cancer cell lines: lung cancer cells(A549). stomach cancer cells(KATO) and neuroglioma cells(SUN-1118. U-87MG, U-373MG). We injected the boiled extracts of realgar $50{\mu}g$. $100{\mu}g$ to cultural media( ml )for 24 hours. We measured the killing effects on 5 kinds of cancer cells through inverted and fluorescence microscope, the suppressive effects on viability of those cells via XTT assay and the effects on the revelation of Bax and Bcl-2 proteins related to apoptosis by western blotting. Results : In the changes of morphology, the extracts of realgar showed more significant killing effects on all cancer cells. especially KATO, SNU-1118, U-87MG, U-373MG, than the control group with dose dependence, which was statistically significant. In XTT assay, the extracts of realgar showed more suppressive effects on viability of all cancer cells, especially KATO and U-373MG, than the control group with dose dependence, which was statistically significant. In the revelation of proteins related to apoptosis, the extracts of realgar increased the level of Bax and decreased that of Bcl-2 in all cancer cells with dose dependence. Conclusions : We identified that realgar had more anti-tumor effects on stomach cancer and neuroglioma than on lung cancer in the experiments above. However, these basic experiments were performed in vitro. We hope the anti-tumor effects of realgar will be practically identified through more progressive research.

  • PDF

FCST(기능적 뇌척주요법)를 병행한 한의 치료로 만성편두통 환자의 두통과 오심을 치료한 증례 보고 1례 (A Case Report of Improvement in Chronic Migraine Headache and Nausea with Korean Medicine Treatment and FCST (Functional Cerebrospinal Therapy))

  • 차지윤;정은선;김찬영;김현태;이영준;설인찬;김윤식;유호룡;조현경
    • 대한한방내과학회지
    • /
    • 제39권4호
    • /
    • pp.784-793
    • /
    • 2018
  • Objective: Chronic migraine is a headache syndrome accompanied by nausea, dyspepsia, depression, and insomnia and it reduces the quality of life. The present case revealed that Korean medicine treatment and Functional Cerebrospinal Therapy (FCST) can reduce headache and nausea in patients with chronic migraine. Method: A 39-year-old female patient with chronic migraine visited Dunsan Korean Medicine Hospital. She had headache combined with moderate nausea and wanted to reduce her dose of almotriptan. We treated her with Korean medicine, including acupuncture, herbal medicine, and a Chuna treatment based on FCST. We evaluated her symptoms using a Numeric Rating Scale (NRS) for headache and nausea every day. Result: After 22 days of treatment, the NRS of headache and nausea had reduced. Her dose of almotriptan was also reduced and the patient felt improvement of in her quality of life. Conclusion: We suggest that Korean medicine treatment combined with FCST can improve the headache and nausea of chronic migraine patients.

Pyrazinamide에 의한 전격성 간부전 1예 (A Case of Pyrazinamide Induced Fulminant Hepatic Failure)

  • 문대성;장태원;옥철호;정만홍;유찬희;송준영;김성은;김자경;장리라;이은영;정규식
    • Tuberculosis and Respiratory Diseases
    • /
    • 제63권5호
    • /
    • pp.435-439
    • /
    • 2007
  • PZA에 의한 독성 간염은 약 2% 정도 보고되고 있으나 전격성 간염으로 진행하여 사망하는 경우는 드물게 보고되고 있다. 본 증례에서는 항결핵제에 의해 중증 독성 간염을 보였다가 회복된 후 저용량의 PZA을 재투여 하고 전격성 간염으로 진행하는 양상을 보였다. 이번 사례를 통해 저용량의 PZA를 투약시 전격성 간부전으로 진행하는 경우를 경험했고 항결핵제 투여시 면밀한 관찰이 필요하고 항결핵 약제 투여시 신중을 기울여야겠다.

인체폐암세포 NCI-H460 및 A549의 apoptosis 유발에 미치는 삼기보배탕의 영향 (Induction of Apoptosis by Samgibopae-tang in Human Non-small-cell Lung Cancer Cells)

  • 허만규;허태율;김기탁;변미권;김진영;심성흠;김광록;감철우;박동일
    • 대한한방내과학회지
    • /
    • 제28권3호
    • /
    • pp.473-491
    • /
    • 2007
  • Objectives : This study was designed to investigate the antiproliferative activity of the water extract of Samgibopae-tang (SGBPT) in NCI-H460 and A549 non-small-cell lung cancer cell lines Methods : In this study, we measured the subsistence, form of NCI-H460 and A549 non-small-cell lung cancer cell by hemocytometer and DAPI staining. In each cell, we analyzed DNA fragmentation. reverse transcription-polymerase chain reaction and measured activity of caspase-3, caspase-8 and caspase-9. Results and Conclusions : We found that exposure of A549 cells to SGBPT resulted in growth inhibition in a dose-dependent manner. butSGBPT did not affect the growth of NCI-H460 cells. The antiproliferative effect by SGBPT treatment in A549 cells was associated with morphological changes. SGBPT treatment partially induced the expression of DR5 cells and the expression of Faswas markedly increased in both transcriptional and translational levels in A549 cells. SGBPT treatment partially induced the expression of Bcl-2, Bcl-XL and the expression of Bid was markedly decreased in translational levels in A549 cells. However, SGBPT treatment did not affect the expression of IAP family in A549 orNCI-H460 cells. SGBPT treatment partially induced the expression of caspase-3, caspase-8, caspase-9 activity which markedly increased in a dose-dependent manners in A549 cells. The fragmental development of PARP and ${\beta}$-catenin protein was observed in A549 cells by SGBPT treatment. SGBPT treatment induced the expression of PLC-${\gamma}1$ protein which decreased in A549 cells. SGBPT treatment partially induced the expression of DFF45/ICAD which markedly increased in a dose-dependent manner in A549 cells. Taken together. these findings suggested that SGBPT-induced inhibition of human lung carcinoma did not affect NCI-H460 cell growth. However, SGBPT-induced inhibition of human lung carcinoma A549 cell growth was associated with the induction of death receptor and mitochondrial pathway. The results provided important new insights into the possible molecular mechanisms of the anti-cancer activity of SGBPT.

  • PDF

그레이브스 갑상선기능항진증 환자의 방사성옥소($^{131}I$) 치료시 실제 유효반감기의 측정 (Measurements of Actual Effective Half-Life in $^{131}I$ Therapy for Graves' Hyperthyroidism)

  • 소용선;김명선;권기현;김석환;김태형;한상웅;김은실;김종순
    • 대한핵의학회지
    • /
    • 제30권1호
    • /
    • pp.77-85
    • /
    • 1996
  • 목적 : 그레이브스 갑상선기능항진증 환자에서 개개인마다 유효반감기가 차이가 있기 때문에, 방사성옥소 치료시 용량산출법에서, 고정된 유효반감기를 사용하는 경우에는 환자에 따라 과용량 뿐만아니라, 부족한 용량을 투여하게 되는 문제점이 있다. 저자들은 환자마다 다양하게 나타나는, 유효반감기를 $^{131}I$ 치료의 효과를 결정하는 가능한 한 인자로서 평가하고, 방사성옥소 투여후에 실제 유효반감기를 추정하고, 이를 기준으로 환자에게 실제 흡수된 방사선 흡수선량을 구하고 예정 흡수선량에 도달하기 위해 필요한 조사선량을 추정하기 위해서 본 연구를 시작했다. 대상 및 방법 : 대상은 1995년 4월부터 본원의 갑상선 클리닉을 방문한 환자중 그레이브스병 갑상선기능항진증으로 진단받았으나 항갑상선제를 장기간 복용에도 불구하고 관해를 유도하지 못했던 경우와, 항갑상선제에 대한 부작용으로 복용할 수 없는 환자 및 환자가 수술적 치료를 거부한 12명의 환자를 대상으로 방사성옥소 치료를 실시하였다. 수정된 Quimby-Marrinelli[투여량(MBq)=$absorbed\;dose(100Gy){\times}thyroid\;weight(g){\times}25{\div}T_{1/2}(day){\div}24hr$ $^{131}I$ uptake(%)]공식에 의해서 계산된 용량을 기준으로 방사성옥소를 투여한 후에 24, 48, 72, 96, 120시간당 방사성 옥소의 갑상선흡수율을 구한후 생물학적반감기, 유효반감기, 흡수선량을 구하였다. 결과: 1) 환자들에서 방사성옥소 투여시 실제 생물학적반감기는 9.5일에서 67.2일까지 다양하게 나타났고 평균 $21{\pm}13.0$(S.D.)일 이었다. 유효반감기는 평균 $5.3{\pm}0.88$(S.D.)일 이었으며 4.3일에서 7.1일까지였다. 2) 평균 방사성옥소 투여량은 532MBq(S.D.=${\pm}254$), 이때 실제 흡수선량은 112Gy(S.D.=${\pm}50.9$)였고, 갑상선조직 1그람당 100Gy의 흡수선량의 도달에 필요한량은 평균 583MBq(S.D.=${\pm}385$)였으며 평균 51MBq의 추가 용량투여가 필요하였다. 3) 방사성옥소의 추적자용량과 치료량에서의 갑상선 옥소섭취율의 변화는 t 값이 3.85, p<0.001로서 유의수준 0.01에서 유의한 차가 인정되었다. 4) 갑상선 중량측정에 있어서 갑상선스캔과 초음파사이에 유의한 차이를 보이지 않았다. 5) 유효반감기, 갑상선중량, 치료전과 치료후의 방사성옥소섭취율은, 40세 이전과 40세 이후의 양군에 있어서 유의한 차이를 보이지 않았다. 결론 : 그레이브스병 환자의 방사성옥소 치료시 용량결정 방법에서 실제 유효반감기를 이용한 방법은, 치료자가 목표로 한 흡수선량을 환자들에게 되도록 정확하게 투여하여, 방사성옥소 투여 후 잦은 빈도로 발생하는 갑상선기능저하증과, 치료실패의 빈도를 줄일 수 있을 것으로 생각한다.

  • PDF

생부자(生附子) 및 삼부탕(蔘附湯)의 aconitine 함량 분석 및 삼부탕 단회투여 독성시험 (Single Oral Dose Toxicity Study and Aconitine Content Analysis of Raw Aconiti Tuber and Sambu-tang)

  • 정해룡;손변우;김경철;신순식;황원덕
    • 대한한방내과학회지
    • /
    • 제37권3호
    • /
    • pp.427-441
    • /
    • 2016
  • Objectives: This study investigated the aconitine contents analysis of Buja extracts (raw material of Buja, hot water extract of Buja, and hot water extract of Sambu-tang) and the single oral dose toxicity of Sambu-tang-R in six-week-old Sprague-Dawley rats in order to compare the toxicity of Buja extracts.Methods: Aconitine content analysis is that Buja extracts were hold purity test. To detect single oral dose toxicity, six-week-old Sprague-Dawley rats were divided into two groups, a normal control group and a sambutang-R (2,000 mg/kg) group. For 14 days of treatment, clinical signs, body weight, clinical chemistry, necropsy, and histopathology were examined.Results: The aconitine contents of the Buja extracts were Buja-RH (0.1738%), Buja-RD (0.1746%), and Sambu-tang-R (0.0961%). There were no cases of death in either the control group or the experimental group. Nor was there any disorder to the clinical signs or any significant change in body weight in either group. There was no significant change of clinical chemistry or disorder of necropsy findings in either the control or the experimental group. And there was no difference in histopathological findings in comparing the control group with the experimental group.Conclusions: These results suggest that the aconitine content of the hot water extract of Buja was similar to the raw material of Buja, but the hot water extract of Sambu-tang had greatly decreased aconitine content. These results also suggest that a single oral lethal dose of Sambu-tang-R for Sprague-Dawley rats exceeds 2,000 mg/kg for both female and male rats.

자연발생 또는 백신접종후 생긴 HBsAg에 대한 항체의 지속성과 Anamnestic Response (Persistence and Anamnestic Response of Antibody to HBsAg Induced by Natural Immunization or Vaccine Treatment)

  • 정환국;선희식;정규원;노재철;김부성
    • Journal of Preventive Medicine and Public Health
    • /
    • 제20권2호
    • /
    • pp.280-286
    • /
    • 1987
  • For evaluating the boosting (anamnestic) effects of the most recent commercially produced plasma derived heat-inactivated hepatitis B vaccine (A. Co.), 117 adults with naturally acquired antibody to hepatitis B surface antigen (anti-HBs) were selected at random. In addition, out of case immunized at zero and 1 month, and boosted at 6 months (primary boosting) by conventional vaccine (B. Co), inactivated by pepsin digestion and formalin treatment, 11 cases who showed elevated titer after primary boosting were also submitted to the study. The results were as follows: 1) Out of the 117 subjects with naturally acquired anti-HBs, 6(5.1%) showed isolated anti-HBs and the titers were below 10 ratio units (RU). Negative seroconversion was seen in 4(3.4%) of the 117 cases at 12 months after the screening and, of these cases, 3 showed isolated anti-HBs and the titers were below 10 RU. 2) Eighty-three percent of the cases with naturally acquired isolated anti-HBs below 10 RU did not respond to a booster injection with 3 us dose of A. Co. vaccine at all, but 90% of the other subjects responded. 3) The anti-HBs titers of all the 11 cases who showed a rise of more than 10 RU (increased GMT, 28.04) at one month after primary booster injection by $20{\mu}g$ dose of B. Co. vaccine decreased at 19 months after the primary booster. And 3 subjects (27.3%) of the 11 reached negative seroconversion. All of the 11 cases, who had secondary booster injection with $3{\mu}g$ dose of A. Co. vaccine at 19 months after primary boosting, showed increased anti-HBs titer at least 20 RU or more (increased GMT, 57. 72) at one month after the boosting. According to the above results in the anti-HBs screening survey for the purpose of immunization with hepatitis B vaccine, subjects with isolated anti-HBs below 10 RU should be regarded as being in an unimmunized state. In cases who are in risk circumstances, immunized primarily with a $20{\mu}g$ dose of B. Co. vaccine, a secondary booster injection should be given within 2 years after initiation of primary immunization and a $3{\mu}g$ booster dose of A. Co. vaccine can be reliably used.

  • PDF

≪상한론≫ 탕제(湯劑)에서 반하(半夏)의 일일 복용량 수정 (Revisoin of the Daily Dose of Pinelliae Tuber in Treatise on Cold Damage Diseases)

  • 김인락
    • 대한본초학회지
    • /
    • 제35권1호
    • /
    • pp.19-25
    • /
    • 2020
  • Objects : The daily dose of Pinelliae Tuber in ≪Treatise on Cold Damage Diseases≫ is half seung in volume, two and half ryang in weight, and fifteen in total number. But the daily dose should be a whole number. So I found out the background of this setting and correct solution. Methods : I searched Classics of Traditional Medicine, found out the background of the daily dose setting, solution. Results : The daily dose of Pinelliae tuber in ≪Hangdi's Internal Classic Miraculous Pivot≫, ≪Bohenggyuljangbuyongyakbeobyo≫ is half seung. ≪Treatise on Cold Dameage Diseases≫ followed the same daily dose of that because it referred to these books. In ≪Synopsis of Prescription of the Golden Chamber≫, the daily dose of that is half seung, one or two seung. The half seung of the Pinelliae Tuber is thirty three mL, but the diameter is 1~1.5 cm that accurate measurement by volume is difficult. The daily dose by weight is correct considering the unity of marking of the daily dose, accuracy of measurement, the fact that Pinelliae Tuber is currently distributed by cutting. So, two ryang is correct which is thirteen gram. Conclusions : Considering the traditionality, the convenience of measurement, the daily dose of Pinelliae Tuber in the ≪Treatise on Cold Damage Diseases≫ is half seung, but considering the unity, accuracy, current state of distribution, it is correct that the daily dose of it is two ryang. It corresponds to thirteen gram.

한국성인 남성을 대상으로 한 방사성옥소의 갑상선 섭취율에 따른 각 장기별 흡수선량 평가 (Assessment of Absorbed Dose of by Organ according to Thyroidal Uptake of Radioactive Iodine for Adult Korean Males)

  • 김정훈;임창선;황주호
    • 한국의학물리학회지:의학물리
    • /
    • 제18권4호
    • /
    • pp.187-193
    • /
    • 2007
  • 한국인의 생리적 특성에 맞는 방사성핵종의 체내 흡수선량 평가를 위한 일환으로 한국 성인 남성 28명을 대상으로 $^{131}|$을 경구투여 후 갑상선섭취율 및 소변 일일배설률을 산정하고 각 장기별 흘수선량을 평가하였다 그 결과, 첫째, 투여 24시간 후 갑상선이 평균 19.70%의 섭취율과 71.12%의 소변 일일배설률을 나타냈다. 둘째 본 연구에서 산출한 갑상선섭취율과 기존 ICRP에서 제시하는 갑상선섭취율 30%에 따른 전신유효선량은 각각 1.464E-08 Sv, 2.189E-08 Sv로 약 1.5배의 차이를 나타났다. 정량적인 방사성 옥소의 흡수선량 평가를 위해서는 기존 ICRP에서 제시하는 자료에 의존하기 보다는 인종별 새로운 측정을 통해 각 핵종별 자료의 확보만이 체내피폭평가시 오류를 최소화 할 수 있다.

  • PDF